Rx License-Rx

YAR01-06

An End-to-End Platform for Discovering and Validating Clinically Actionable Tumor Antigens

A unique platform that combines comprehensive tumor antigen discovery with direct validation of HLA-presented peptides, bridging the gap between predicted targets and clinically actionable opportunities in immunotherapy and diagnostics.

Intelligence Memo

Owner: University-originated technology office

Core category: Research Tools

Therapeutic area: Oncology

Indication:

Modality: Biologic

Focus tags: Oncology, Immunology

Technology tags: Biologic, Cell/Gene Therapy, Diagnostic / Biomarker

Mechanism:

Development stage: Early / Discovery

Patent status: Needs review

Availability: Available for license

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets BMS / 2seventy — Cell therapy portfolio logic; needs differentiated antigen strategy. Gilead / Kite — Manufacturing and oncology BD infrastructure already exists. Regeneron — Deep oncology biologics and T-cell engager adjacency.

Development Strategy to Increase PoS

First indication: a molecularly selected tumor segment where a small proof-of-mechanism study is credible

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero

Best next experiment: Run the smallest independent study that validates: Use a centralized CDMO, lock the release assay early, and design the first trial around tumor-antigen evidence rather than broad basket ambition.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.